Dr. Matthew J. Armstrong from the University of Birmingham, UK observed that, "Liraglutide (and other GLP-1 analogues) appears safe to use in overweight patients with diabetes that have mild to moderately deranged liver enzymes." Plus he noted that, "In addition, this group of drugs may have a beneficial effect in patients with underlying liver disease secondary to fatty liver and steatohepatitis. This, however, requires prospective controlled-studies, which we are undertaking in Birmingham, to further understand its use in fatty liver disease."

Among 4,442 patients with type 2 diabetes in the trials, 2,241 (50.8%) had an abnormal alanine transaminase at baseline (mean ALT 33.8 IU/L in women; 47.3 IU/L in men). Liraglutide 1.8 mg reduced ALT in these patients vs placebo (8.20 vs 5.01 IU/L; p=0.003), the researchers reported.

Adverse effects with 1.8 mg liraglutide were similar between patients with and without baseline abnormal ALT.

A study conducted at Jothydev’s Diabetes Research Center also found that Liraglutide can lower liver enzymes in type 2 diabetes